- Report
- March 2024
- 143 Pages
Global
From €3787EUR$3,899USD£3,267GBP
- Report
- February 2024
- 118 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Report
- August 2022
- 161 Pages
Global
From €7284EUR$7,500USD£6,284GBP
- Report
- January 2022
- 419 Pages
Global
From €9227EUR$9,500USD£7,960GBP
- Report
- July 2018
- 37 Pages
Global
From €9713EUR$10,000USD£8,379GBP
- Drug Pipelines
- February 2018
- 35 Pages
Global
From €9713EUR$10,000USD£8,379GBP
- Drug Pipelines
- February 2018
- 17 Pages
Global
From €9713EUR$10,000USD£8,379GBP
- Report
- February 2018
- 17 Pages
Global
From €9713EUR$10,000USD£8,379GBP
- Drug Pipelines
- August 2020
- 90 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Report
- April 2023
- 156 Pages
Global
€4856EUR$5,000USD£4,189GBP
- Report
- April 2023
- 114 Pages
Global
€3399EUR$3,500USD£2,933GBP
- Report
- February 2024
- 84 Pages
Global
From €3500EUR$3,860USD£3,125GBP
- Drug Pipelines
- June 2021
- 95 Pages
Global
From €1943EUR$2,000USD£1,676GBP
Fluticasone Propionate is a corticosteroid used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is used to reduce inflammation in the airways, which helps to reduce symptoms such as wheezing, coughing, and shortness of breath. It is available in both inhaler and nasal spray forms, and is often prescribed in combination with other medications. Fluticasone Propionate is a widely used medication in the respiratory drug market, and is often prescribed as a first-line treatment for asthma and COPD.
The Fluticasone Propionate market is highly competitive, with many pharmaceutical companies offering their own branded versions of the drug. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and Sanofi. Other companies such as Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals also offer generic versions of the drug. Show Less Read more